mrpl-24 Antibody

What is MRPL24 and why is it significant for mitochondrial research?

MRPL24 (mitochondrial ribosomal protein L24) is a crucial component of the large 39S subunit of the mitochondrial ribosome (mitoribosome). As a nuclear-encoded protein that facilitates mitochondrial protein synthesis, MRPL24 plays an essential role in maintaining proper mitochondrial function. Mitoribosomes differ significantly from their cytoplasmic counterparts, with an estimated 75% protein to rRNA composition compared to prokaryotic ribosomes, where this ratio is reversed. Another notable difference is that mammalian mitoribosomes lack the 5S rRNA present in prokaryotic ribosomes. The MRPL24 protein is more than twice the size of its E. coli counterpart (EcoL24), highlighting evolutionary divergence in mitochondrial translation machinery. Research focusing on MRPL24 contributes to our understanding of mitochondrial translation, which is crucial for cellular energy production and metabolic homeostasis .

What are the basic characteristics of MRPL24 that researchers should be aware of?

Researchers working with MRPL24 should be familiar with these fundamental characteristics:

Understanding these characteristics is crucial for experimental design, antibody selection, and data interpretation in MRPL24 research .

How should I select the appropriate MRPL24 antibody for my specific experimental needs?

When selecting an MRPL24 antibody, consider these key factors:

• Experimental Application: Different applications require antibodies with specific validation profiles. For Western blot applications, ensure the antibody has been validated to detect bands at the expected molecular weight (approximately 25-32 kDa for MRPL24). For immunoprecipitation, choose antibodies specifically validated for protein pulldown efficiency. For immunohistochemistry or immunofluorescence, select antibodies with demonstrated specificity in fixed tissues/cells.

• Species Reactivity: Verify that the antibody recognizes MRPL24 in your experimental organism. Most commercial MRPL24 antibodies show reactivity with human, mouse, and rat MRPL24, but cross-reactivity with other species may vary and should be confirmed.

• Antibody Format: Consider whether your experiment requires a conjugated or unconjugated antibody. Most MRPL24 antibodies are available in unconjugated form and can be used with secondary detection systems.

• Clonality: Polyclonal antibodies offer broad epitope recognition but may have batch-to-batch variation. Currently, most MRPL24 antibodies are rabbit polyclonal antibodies.

• Immunogen Information: Review the immunogen used to generate the antibody to ensure it will recognize your region of interest. For example, some MRPL24 antibodies are raised against specific peptide regions (e.g., amino acids 101-150 of human MRPL24) .

What are the standard protocols for Western blot analysis of MRPL24 and how should I optimize them?

Standard Western Blot Protocol for MRPL24 Detection:

• Sample Preparation:

  • Prepare cell/tissue lysates in RIPA buffer supplemented with protease inhibitors

  • Include positive controls such as HEK-293 cells or mouse liver tissue, which have demonstrated MRPL24 expression

  • Load 20-50 μg of total protein per lane

• Gel Electrophoresis and Transfer:

  • Use 10-12% SDS-PAGE gels for optimal resolution around 25-32 kDa

  • Transfer to PVDF or nitrocellulose membranes (PVDF may provide better results for mitochondrial proteins)

• Blocking and Antibody Incubation:

  • Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

  • Incubate with primary MRPL24 antibody at dilutions ranging from 1:500 to 1:8000 in blocking buffer overnight at 4°C

  • Wash 3-5 times with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody (typically anti-rabbit IgG) at 1:2000-1:10000 dilution for 1 hour at room temperature

• Detection:

  • Develop using enhanced chemiluminescence (ECL) reagents

  • Expected band: 25-32 kDa

Optimization Tips:

• Always perform a dilution series (e.g., 1:1000, 1:2000, 1:4000, 1:8000) with a new antibody lot to determine optimal signal-to-noise ratio

• For low abundance detection, consider extending primary antibody incubation to 48 hours at 4°C

• If background is high, increase the number or duration of washing steps

• Validate specificity using MRPL24 overexpression lysates compared to control lysates .

How can I use MRPL24 antibodies for immunoprecipitation studies, and what controls should I include?

For immunoprecipitation of MRPL24:

• Sample Preparation:

  • Lyse cells in a non-denaturing buffer (e.g., NP-40 buffer with protease inhibitors)

  • Clear lysate by centrifugation (14,000 × g for 10 minutes at 4°C)

  • Pre-clear with protein A/G beads to reduce non-specific binding

• Immunoprecipitation:

  • Add 0.5-4.0 μg of MRPL24 antibody to 1.0-3.0 mg of total protein lysate

  • Incubate overnight at 4°C with gentle rotation

  • Add protein A/G beads and incubate for 2-4 hours at 4°C

  • Wash beads 4-5 times with lysis buffer

  • Elute proteins by boiling in Laemmli buffer and analyze by Western blot

• Essential Controls:

  • Isotype Control: Include a matched isotype antibody (e.g., normal rabbit IgG) to identify non-specific pulldown

  • Input Control: Run 5-10% of the pre-IP lysate to confirm target protein presence

  • No-Antibody Control: Process lysate without antibody addition to identify non-specific binding to beads

  • Positive Cell Line: Include HEK-293 cells as positive control, which have confirmed MRPL24 expression

• Validation Approaches:

  • Confirm IP by Western blot using a different MRPL24 antibody that recognizes a distinct epitope

  • For co-IP studies, validate interactions by reverse IP (using antibodies against the interacting partner)

  • Consider crosslinking studies to capture transient interactions in the mitochondrial translation system .

How can I use MRPL24 antibodies to investigate mitoribosome assembly and integrity?

Investigating mitoribosome assembly with MRPL24 antibodies requires multifaceted approaches:

• Sucrose Gradient Fractionation with Immunoblotting:

  • Lyse mitochondria in non-denaturing buffer

  • Layer lysate onto 10-30% sucrose gradients and ultracentrifuge (100,000 × g for 4 hours)

  • Collect fractions and analyze by Western blot with MRPL24 antibody

  • Compare distribution patterns with markers for fully assembled mitoribosomes (e.g., mitochondrial rRNAs) and free subunits

  • Abnormal distribution patterns may indicate assembly defects

• Co-Immunoprecipitation of Mitoribosomal Complexes:

  • Use MRPL24 antibodies to pull down associated mitoribosomal components

  • Analyze by mass spectrometry to identify the full complement of interacting proteins

  • Compare results under normal and stress conditions to identify dynamics of mitoribosome assembly

• Proximity Labeling Methods:

  • Express MRPL24 fused to BioID or APEX2

  • After biotin labeling, use streptavidin pulldown followed by immunoblotting with MRPL24 antibody

  • This approach identifies proximal proteins in the intact mitoribosome

• Analysis in Disease Models:

  • Compare MRPL24 incorporation into mitoribosomal complexes in cells with pathogenic variants in other mitoribosomal proteins (e.g., MRPL39, MRPL15)

  • This approach can reveal interdependencies in mitoribosome assembly

This research is particularly important considering findings that pathogenic variants in mitoribosomal proteins like MRPL39 can cause large mitoribosomal subunit instability, leading to mitochondrial disease .

What troubleshooting strategies should I apply when MRPL24 antibody results show inconsistencies across different cell or tissue types?

When MRPL24 antibody results show inconsistencies across different experimental systems:

These systematic approaches can help determine whether inconsistencies represent technical issues or biologically meaningful variations in MRPL24 expression or modification .

How can I use MRPL24 antibodies to study mitochondrial translation in disease models?

MRPL24 antibodies can be powerful tools for investigating mitochondrial translation defects in disease models:

• Mitoribosome Stability Assessment:

  • Compare MRPL24 protein levels across disease models using standardized Western blot protocols

  • Decreased MRPL24 levels may indicate mitoribosome instability, as seen with pathogenic variants in other mitoribosomal proteins

  • Correlate with levels of other large subunit proteins to distinguish between global and specific effects

• Mitochondrial Translation Assays with Immunofluorescence Correlation:

  • Perform metabolic labeling of mitochondrial translation products with 35S-methionine/cysteine in the presence of cytoplasmic translation inhibitors

  • In parallel, quantify MRPL24 levels by immunofluorescence or Western blot

  • Correlate translation efficiency with MRPL24 expression/localization to establish functional relationships

• Ribosome Profiling with MRPL24 Immunoprecipitation:

  • Use MRPL24 antibodies to purify actively translating mitoribosomes

  • Extract and sequence associated mRNAs to identify translation patterns

  • Compare profiles between control and disease models to identify translation bottlenecks

• Investigating MRPL24 Interactions in Disease States:

  • Use co-immunoprecipitation with MRPL24 antibodies followed by mass spectrometry

  • Compare interaction partners between healthy and disease samples

  • Identify altered protein-protein interactions that may contribute to translation defects

• Rescue Experiments:

  • In models with identified mitoribosomal defects, perform rescue with wild-type MRPL24

  • Use MRPL24 antibodies to confirm expression levels of exogenous protein

  • Correlate rescue of mitochondrial translation with restoration of MRPL24 incorporation into mitoribosomes

This approach is particularly relevant given research showing that pathogenic variants in other mitoribosomal proteins cause pediatric-onset mitochondrial disease through mechanisms involving large mitoribosomal subunit instability .

What are the optimal immunohistochemistry conditions for MRPL24 detection in different tissue types?

Optimizing immunohistochemistry protocols for MRPL24 detection requires tissue-specific adjustments:

General IHC Protocol for MRPL24 Detection:

• Tissue Preparation:

  • Formalin-fixed paraffin-embedded (FFPE) sections: 4-6 μm thickness

  • Fresh frozen sections: 8-10 μm thickness, fixed in cold acetone

• Antigen Retrieval (critical for FFPE tissues):

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) for 20 minutes

  • For tissues with high mitochondrial content (heart, muscle), EDTA buffer (pH 9.0) may provide better results

• Blocking and Antibody Application:

  • Block with 5-10% normal goat serum in PBS for 1 hour at room temperature

  • Apply MRPL24 antibody at 1:100-1:300 dilution overnight at 4°C

  • Wash thoroughly (3 × 5 minutes in PBS-T)

  • Apply appropriate HRP-conjugated secondary antibody (1:200-1:500) for 1 hour at room temperature

• Signal Development and Counterstaining:

  • Develop with DAB substrate for 3-5 minutes (monitor under microscope)

  • Counterstain with hematoxylin for nuclear visualization

  • Mount with permanent mounting medium

Tissue-Specific Optimizations:

Validation Approaches:

• Include positive control tissues (colon, liver) in each staining run

• Use mitochondrial markers (VDAC, COX IV) on serial sections to confirm mitochondrial staining patterns

• For high-resolution analysis, consider combining with mitochondrial markers in dual immunofluorescence studies .

How does the performance of different MRPL24 antibodies compare across various research applications?

Comparing the performance of different MRPL24 antibodies across applications reveals important considerations for experimental design:

Key Performance Factors:

• Epitope Accessibility: Antibodies recognizing different epitopes (e.g., N-terminal vs. internal regions) may perform differently depending on protein conformation or interaction status

• Post-Translational Modifications: Antibodies may have differential sensitivity to phosphorylated or otherwise modified forms of MRPL24

• Cross-Reactivity: While most antibodies show specified reactivity to human, mouse, and rat MRPL24, performance may vary across these species

• Background in Specific Applications: Some antibodies perform excellently in Western blot but may show higher background in IHC/IF applications

For critical experiments, researchers should validate multiple antibodies and select the best performer for their specific application and experimental system .

What approaches can be used to combine MRPL24 antibody detection with other mitochondrial markers for comprehensive analysis?

Integrating MRPL24 detection with other mitochondrial markers enables multilayered analysis of mitochondrial biology:

• Multiplexed Immunofluorescence Approaches:

  • Dual Immunostaining: Combine MRPL24 (rabbit polyclonal) with mouse antibodies against other mitochondrial compartments:

    • Outer membrane: Tom20, VDAC

    • Inner membrane: Complex I-V subunits

    • Matrix: HSP60, mtHSP70

  • Sequential Staining Protocol:

    • Apply first primary antibody overnight at 4°C

    • Detect with spectrally distinct fluorophore-conjugated secondary

    • Block with excess unconjugated secondary antibody

    • Apply second primary antibody and detect with different fluorophore

    • Include single-stained controls to verify specificity

• Combined Protein and Nucleic Acid Detection:

  • RNA FISH with Immunofluorescence:

    • Detect mitochondrial rRNAs (12S, 16S) using fluorescent probes

    • Follow with MRPL24 immunodetection

    • This approach reveals spatial relationships between MRPL24 protein and mitoribosomal RNA

  • mtDNA with MRPL24 Colocalization:

    • Label mtDNA with PicoGreen or anti-DNA antibodies

    • Counterstain with MRPL24 antibodies

    • Analyze proximity to evaluate translation-transcription coupling

• Functional Mitochondrial Stains with MRPL24 Immunodetection:

  • Membrane Potential with MRPL24:

    • Stain live cells with TMRM or JC-1 for membrane potential

    • Fix and immunostain for MRPL24

    • Correlate translation machinery distribution with functional status

  • Superoxide Production with MRPL24:

    • Use MitoSOX Red for superoxide detection

    • Fix and perform MRPL24 immunodetection

    • Analyze whether oxidative stress affects mitoribosome distribution

• Proximity Ligation Assay (PLA) Applications:

  • Combine MRPL24 antibody with antibodies against potential interaction partners

  • PLA signal occurs only when proteins are within 40 nm

  • Useful for validating interactions within the mitoribosome complex

• Image Analysis Considerations:

  • Use deconvolution or super-resolution microscopy for detailed colocalization

  • Apply appropriate colocalization metrics (Pearson's correlation, Manders' coefficients)

  • Consider 3D analysis to capture the full mitochondrial network

These approaches enable researchers to place MRPL24 function in the broader context of mitochondrial biology and disease mechanisms .

How does MRPL24 dysfunction contribute to mitochondrial disease pathology?

While direct evidence for MRPL24 mutations in human disease is still emerging, research on related mitoribosomal proteins provides valuable insights into how MRPL24 dysfunction might contribute to mitochondrial pathology:

What are the emerging methodologies for studying MRPL24 interactions in the context of mitoribosome research?

Advanced methodologies for investigating MRPL24 within the mitoribosome context are rapidly evolving:

• Cryo-Electron Microscopy (Cryo-EM) Combined with Immunolabeling:

  • High-resolution structural analysis of mitoribosomes with MRPL24 antibody-gold labeling

  • Reveals precise positioning and conformational changes during translation

  • Enables comparison between normal and disease-associated variants

  • Can be combined with functional states (elongation, termination) to capture dynamic roles

• Quantitative Interactomics Approaches:

  • SILAC-IP: Stable isotope labeling with amino acids followed by MRPL24 immunoprecipitation

  • TMT-MS: Tandem mass tag mass spectrometry to quantify differential interactions

  • BioID/TurboID: Proximity labeling with MRPL24 fusion proteins

  • These approaches identify both stable and transient interaction partners under various conditions

• Live-Cell Imaging of Mitoribosome Dynamics:

  • CRISPR knock-in of fluorescent tags to endogenous MRPL24

  • Combination with super-resolution microscopy (STED, PALM, STORM)

  • Enables tracking of mitoribosome assembly, movement, and activity in real-time

  • Can be combined with translation reporters to correlate structure with function

• Integrative Multi-Omics Approaches:

  • Combined analysis of:

    • Proteomics: MRPL24 levels and interactome

    • Transcriptomics: mtDNA-encoded transcript levels

    • Metabolomics: Downstream effects on mitochondrial metabolism

    • Provides comprehensive view of MRPL24's role in cellular homeostasis

• Nanopore Sequencing Applications:

  • Direct RNA sequencing to identify mitoribosome-associated transcripts

  • Detection of RNA modifications that may influence MRPL24-RNA interactions

  • Development of antibody-based nanopore approaches for protein detection

• Single-Molecule Techniques:

  • Optical tweezers or magnetic tweezers to study MRPL24's role in mitoribosome mechanics

  • Single-molecule FRET to analyze conformational changes during translation

  • Reveals energy landscapes and kinetic parameters of mitoribosome function

These emerging methodologies provide unprecedented insight into MRPL24's functional roles and may reveal novel therapeutic targets for mitochondrial translation disorders .

How can MRPL24 antibody research contribute to our understanding of mitochondrial evolution and species differences?

MRPL24 antibody research offers unique opportunities to explore mitochondrial evolution and interspecies differences:

• Evolutionary Conservation Analysis:

  • MRPL24 antibodies can be used to examine protein conservation across species

  • While the mitoribosome structure is generally conserved, mitoribosomal proteins show significant sequence divergence

  • MRPL24 is more than twice the size of its bacterial counterpart (EcoL24)

  • Comparative immunoblotting across species can reveal:

    • Size variations

    • Expression level differences

    • Post-translational modification patterns

  • These differences reflect evolutionary adaptations in mitochondrial translation

• Structure-Function Relationships Across Species:

  • Immunoprecipitation studies in different organisms can identify species-specific interaction partners

  • This reveals how mitoribosome composition has evolved to meet different metabolic demands

  • Cross-species reactivity testing of MRPL24 antibodies provides insights into conserved epitopes

  • Regions with high antibody cross-reactivity likely represent functionally critical domains

• Mitoribosome Assembly Pathway Variations:

  • Comparative studies using MRPL24 antibodies can track assembly intermediates across species

  • This reveals evolutionary differences in mitoribosome biogenesis

  • Different organisms may employ distinct chaperones or assembly factors

  • Understanding these differences helps identify universal versus species-specific assembly requirements

• Mitochondrial Disease Modeling:

  • MRPL24 antibodies can validate model systems for studying human mitochondrial diseases

  • Comparing MRPL24 expression, localization, and interactions between human samples and model organisms

  • This approach helps identify which models best recapitulate human mitochondrial translation processes

  • Critical for translational research on mitochondrial disorders

• Evolutionary Adaptations in Mitochondrial Translation:

  • MRPL24 antibody studies in species with unique metabolic adaptations (hibernating mammals, deep-sea organisms, extremophiles)

  • Reveals how mitoribosome composition adapts to extreme environments

  • May identify novel mechanisms for regulating mitochondrial translation under stress

  • Could inform therapeutic approaches for human mitochondrial disorders

This evolutionary perspective provides context for human mitochondrial disease research and may identify conserved targets for therapeutic intervention .

What are the most promising future applications of MRPL24 antibodies in mitochondrial disease research?

MRPL24 antibodies hold significant potential for advancing mitochondrial disease research through several innovative applications:

• Diagnostic Biomarker Development:

  • MRPL24 levels or localization patterns may serve as biomarkers for specific mitochondrial translation disorders

  • Antibody-based assays could provide less invasive diagnostic approaches than current muscle biopsy-dependent methods

  • Particularly valuable for screening pediatric patients with suspected mitochondrial disease

• Therapeutic Response Monitoring:

  • As therapies targeting mitochondrial translation emerge, MRPL24 antibodies can monitor treatment efficacy

  • Changes in mitoribosome assembly and function could provide early indicators of therapeutic response

  • Enabling personalized medicine approaches for mitochondrial disorders

• Drug Discovery Platforms:

  • High-throughput screening systems using MRPL24 antibodies to identify compounds that:

    • Stabilize mitoribosome assembly

    • Enhance mitochondrial translation efficiency

    • Rescue defects caused by pathogenic variants in mitoribosomal proteins

  • May lead to first-in-class therapeutics for currently untreatable mitochondrial diseases

• Artificial Mitoribosome Engineering:

  • MRPL24 antibodies can validate synthetic biology approaches to engineer improved mitoribosomes

  • Potential applications in producing mitochondrial proteins for therapeutic delivery

  • May enable mitochondrial gene therapy approaches previously limited by translation barriers

• Integrated Multi-Omics Disease Modeling:

  • Combining MRPL24 antibody-based proteomics with transcriptomics, metabolomics, and clinical data

  • Creating comprehensive models of mitochondrial disease progression

  • Identifying critical intervention points in disease pathways

  • Recent studies demonstrating multi-omics identification of mitoribosomal subunit instability in MRPL39 variants provide a template for this approach

These future directions highlight how MRPL24 antibody research extends beyond basic science to applications with direct clinical relevance for patients with mitochondrial disorders .

How can researchers integrate MRPL24 antibody studies with emerging mitochondrial research technologies?

The integration of MRPL24 antibody techniques with cutting-edge mitochondrial research technologies creates powerful new investigative approaches:

• Combination with CRISPR-Based Mitochondrial Editing:

  • MRPL24 antibodies can validate effects of precise mtDNA or nuclear gene editing

  • Monitor changes in mitoribosome assembly and function after genetic modification

  • Enable correlation between genetic manipulation and functional outcomes

  • Critical for developing mitochondrial gene therapy approaches

• Integration with Organoid and Patient-Derived Models:

  • Apply MRPL24 antibody techniques to 3D organoid cultures from patients with mitochondrial disease

  • Compare mitoribosome structure and function in affected tissues

  • Validate tissue-specific consequences of mitochondrial translation defects

  • Support personalized medicine approaches for heterogeneous mitochondrial disorders

• Advances in Spatial Transcriptomics and Proteomics:

  • Combine MRPL24 immunodetection with spatial -omics technologies

  • Map mitochondrial translation machinery distribution within tissues

  • Identify regional vulnerabilities to translation defects

  • Reveal cell-type specific responses to mitochondrial dysfunction

• Integration with Mitochondrial Transfer Technologies:

  • Use MRPL24 antibodies to track mitoribosome behavior during mitochondrial transfer

  • Determine whether donor mitochondria transfer translational components to recipient cells

  • Evaluate therapeutic potential of mitochondrial transplantation for translation disorders

  • Advance understanding of intercellular mitochondrial communication

• Artificial Intelligence Applications:

  • Develop machine learning algorithms to analyze complex patterns in MRPL24 immunostaining

  • Identify subtle alterations in mitoribosome distribution that predict disease progression

  • Create automated diagnostic tools for mitochondrial translation disorders

  • Accelerate research through improved image analysis and pattern recognition